|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
on1348379871 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
221022s2022 sz a ob 100 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d GW5XE
|d EBLCP
|d OCLCF
|d VLB
|d ESU
|d OCLCQ
|d OCLCO
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1348481547
|
| 020 |
|
|
|a 9783031085529
|q (electronic bk.)
|
| 020 |
|
|
|a 3031085523
|q (electronic bk.)
|
| 020 |
|
|
|z 9783031085512
|
| 020 |
|
|
|z 3031085515
|
| 024 |
7 |
|
|a 10.1007/978-3-031-08552-9
|2 doi
|
| 035 |
|
|
|a (OCoLC)1348379871
|z (OCoLC)1348481547
|
| 050 |
|
4 |
|a RC848.P6
|b B28 2022eb
|
| 049 |
|
|
|a HCDD
|
| 111 |
2 |
|
|a Baveno International Consensus Workshop
|n (7th)
|
| 245 |
1 |
0 |
|a Portal hypertension VII :
|b proceedings of the 7th Baveno Consensus Workshop : personalized care in portal hypertension /
|c Roberto de Franchis, editor.
|
| 264 |
|
1 |
|a Cham :
|b Springer,
|c [2022]
|
| 264 |
|
4 |
|c ©2022
|
| 300 |
|
|
|a 1 online resource (xxxiv, 692 pages : illustrations (chiefly color))
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Conference proceedings.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 520 |
|
|
|a This book, the seventh in a series of proceedings volumes that began in 1995, reviews the latest developments in the diagnosis and management of cirrhosis and portal hypertension. It addresses a broad range of topics, including: risk stratification, HVPG, non-invasive surrogates for cACLD, CSPH, varices, progression and regression of cirrhosis, impact of etiological therapy on cirrhosis, impact of non-etiological novel therapies on cirrhosis, prevention of first/further decompensation, acute variceal hemorrhage, and Vascular Liver Disorders in Cirrhosis (VALDIG). The book is a compilation of lectures and important consensus statements from the Seventh Baveno International Consensus Workshop on Portal Hypertension, the latest in a series of workshops held every five years for hepatologists with an interest in the field. Portal Hypertension VII offers a valuable reference guide for clinical and research fellows in Gastroenterology and Hepatology and will inspire new research projects in the promising areas identified by the experts of the Baveno VII Faculty.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed November 1, 2022).
|
| 505 |
0 |
|
|a Intro -- Preface -- Thomas D. Boyer, MD (1943-2018)-A Tribute -- Memories of Prof Andrew K. Burroughs, MD (1953-2014) -- Tribute to Roberto J. Groszmann -- Tribute to Prof Luigi Pagliaro (1931-2020) -- Contents -- Contributors -- Part I: Introductory Lectures -- 1: Introduction: Baveno I to Baveno VII ... and Beyond -- Baveno I to VI -- Attendance at the Baveno Workshops -- Publications Derived from the Baveno Workshops -- Impact of the Baveno Consensus on the Medical Literature -- Validation of the Baveno Definitions and Recommendations -- Beyond Baveno VII, the Baveno Cooperation
|
| 505 |
8 |
|
|a The Baveno I-VII Workshops Were a Concerted Effort of the Following -- Speakers and Chairpersons -- References -- 2: New Concepts in Risk Stratification -- Introduction -- Risk Prediction and Probabilistic Thinking -- Diagnosis as a Risk Prediction Problem -- Decision Thresholds and Risk Stratification -- Risk Prediction and the Interpretation of Treatment Effects in Randomized Controlled Trials -- Conclusion -- References -- 3: Clinical Stages and Ordinal Outcomes in Portal Hypertension -- Background -- Definition and Incidence of Decompensation -- Clinical Stages of Cirrhosis
|
| 505 |
8 |
|
|a Ordinal Outcomes -- Examples of Application of an Ordinal Outcome in Compensated Cirrhosis -- Ordinal Outcomes for Randomized Clinical Trials in Cirrhosis -- Sample Size Estimation with Ordinal Compared to Binary Outcomes -- Using Ordinal Outcomes in Portal Hypertension -- Conclusions -- References -- 4: Lifestyle and Genetic Modifiers of Liver Disease Progression -- Lifestyle Modifiers of Liver Disease Progression -- Unhealthy Lifestyle -- Alcohol -- Obesity -- Malnutrition, Sarcopenia, and Frailty -- Cigarette Smoke -- Healthy Lifestyle-Protective Factors -- Physical Activity and Exercise
|
| 505 |
8 |
|
|a Coffee Consumption and Mediterranean Diet -- Genetic Modifiers of Progression of cACLD -- Individual Genetic Variants -- PNPA3 and HSD17B13 -- SERPINA1/Alpha-1 Antitrypsin Deficiency -- NOD2 -- NR1H4/FXR -- Conclusions and Outlook -- References -- Part II: HVPG as a Gold Standard -- 5: HVPG as a Gold Standard: Accuracy Is Essential -- Procedure Technique -- Pressure Measurements and Data Recording -- Technical Aspects -- Diagnosis of Clinically Significant Portal Hypertension (CSPH) and Prediction of Main Outcomes in Patients with Different Etiologies of Cirrhosis -- Variceal Hemorrhage
|
| 505 |
8 |
|
|a Hepatocellular Carcinoma (HCC) -- Survival -- Assessment of HVPG in Patients Receiving NSBBs for Prevention of Variceal Hemorrhage and Decompensation -- HVPG Predicts Risk of Decompensation and Mortality after Hepatic and Non-hepatic Surgery -- Patients with Cirrhosis and HCC: Candidates for Hepatic Resection -- Patients with Cirrhosis Who Undergo Extrahepatic Surgery -- PPG in the Setting of Tips -- PPG Measurement -- Anatomic Location for PPG Measurement -- Optimal PPG Threshold for Portal Hypertensive Bleeding/Ascites -- PPG Thresholds in Overshunting Adverse Events -- References
|
| 650 |
|
0 |
|a Portal hypertension
|v Congresses.
|
| 650 |
|
7 |
|a Portal hypertension
|2 fast
|
| 655 |
|
7 |
|a proceedings (reports)
|2 aat
|
| 655 |
|
7 |
|a Conference papers and proceedings
|2 fast
|
| 655 |
|
7 |
|a Conference papers and proceedings.
|2 lcgft
|
| 655 |
|
7 |
|a Actes de congrès.
|2 rvmgf
|
| 700 |
1 |
|
|a De Franchis, Roberto,
|e editor.
|1 https://isni.org/isni/0000000030314511
|
| 776 |
0 |
8 |
|c Original
|z 3031085515
|z 9783031085512
|w (OCoLC)1317836459
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-031-08552-9
|y Click for online access
|
| 880 |
0 |
|
|6 505-00/(S
|a Part I Introductory Lectures -- Introduction: Baveno I to Baveno VII ... and Beyond -- New Concepts in Risk Stratification -- Clinical Stages and Ordinal Outcomes in Portal Hypertension -- Lifestyle and Genetic Modifiers of Liver Disease Progression -- Part II HVPG as a Gold Standard -- HVPG as a Gold Standard: Accuracy Is Essential -- HVPG as a Gold Standard: Consensus Statements of Panel 1 -- Part III Noninvasive Tools for cACLD and Portal Hypertension -- Results of the Baveno VII Questionnaire on the Use of Noninvasive Tools for cACLD and Portal Hypertension -- Compensated Advanced Chronic Liver Disease (cACLD) -- Noninvasive Detection of Clinically Significant Portal Hypertension with Liver Elastography -- Varices and Screening Endoscopy -- Liver Elastography for Prognostication and Monitoring Patients With Compensated Advanced Chronic Liver Disease -- Spleen Stiffness -- Emerging Non-invasive Markers: Imaging, Blood, and Liver Clearance Tests -- Noninvasive Surrogates for cACLD, CSPH, Varices: Consensus Statements of Panel 2 -- Part IV New Scenarios 1: Introductory Lectures-Progression and Regression of Cirrhosis -- Progression and Regression of Cirrhosis: The Histologic Perspective -- Liver Fibrosis and Its Regression in the Context of Portal Hypertension -- Angiogenesis and Progression of ACLD -- Drugs to Modify Liver Fibrosis Progression and Regression -- Part V New Scenarios 2: Management of ACLD after Removal of the Primary Etiological Factor -- Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease -- Management of ACLD After HBV-Suppression and HCV-Cure -- Management of ACLD After Removal/Suppression of the Etiological Factor: Consensus Statements of Panel 3 -- Part VI New Scenarios 3: Impact of Non-etiological Novel Therapies in the Course of Cirrhosis -- Results of the Baveno VII Questionnaire on the "Impact of Non-etiological Therapies in the Course of Cirrhosis" -- Statins in Compensated and Decompensated Cirrhosis: Approaching the Bedside -- Anticoagulation for Portal Vein Thrombosis in Cirrhosis: An Evidence-Based Approach to When and How -- Novel Approaches and Disease Modifiers to Alter the Course of Cirrhotic Portal Hypertension -- Targeting the Gut Microbiome in Cirrhosis -- Impact of Non-etiological Novel Therapies in the Course of Cirrhosis: Consensus Statements of Panel 4 -- Part VII Clinical Settings 1: Preventing (First) Decompensation -- Prevention of First Decompensation: Questionnaire -- Definition of First Decompensation in Cirrhosis -- Evaluation of the Impact of the Sole Presence of Infection (Without Accompanying Decompensation) in the Natural History of Compensated Cirrhosis -- Evaluation of the Role of Jaundice in the Definition of Decompensation in the Compensated Patients -- Evaluation of the Role of Minimal Perihepatic Ascites, Minimal Hepatic Encephalopathy, and Bleeding Due to Portal Hypertensive Gastroenteropathy in the Definition of Decompensation -- Evaluation of the Role of Sarcopenia in the Definition of Decompensation of the Compensated Patient -- β-Blockers to Prevent Decompensation of Cirrhosis in Compensated Patients With Clinically Significant Portal Hypertension -- Evaluation of the Effect of CSPH, Reduction of HVPG, and Other Factors Predicting the First Decompensation in Cirrhosis -- Preventing (First) Decompensation: Consensus Statements of Panel 5 -- Part VIII Clinical Settings 2: Acute Variceal Bleeding -- General Management of Acute Variceal Bleeding -- Risk Stratification and Prognostic Factors in Variceal Bleeding -- Endoscopic Management: Classic and New Therapies -- Preemptive TIPS (p-TIPS) -- Management of Refractory Variceal Bleeding -- Hepatic Encephalopathy and Acute Variceal Bleeding -- Management of Coagulation in Acute Variceal Bleeding -- Gastric Varices and Ectopic Varices -- Special Settings: Acute Variceal Bleeding and Portal Vein Thrombosis in Cirrhosis -- Clinical Settings 2: Acute Variceal Bleeding-Consensus Statements of Panel 6 -- Part IX Clinical Settings 3: Preventing Further Decompensation -- Concept of Further Decompensation and Recompensation -- Prevention of Variceal Bleeding and Rebleeding -- Prevention of Further Decompensation in Patients With Ascites -- The Impact of Sarcopenia, Frailty, and Malnutrition on Further Decompensation -- Preventing Further Decompensation: Consensus Statements of Panel 7 -- Part X Vascular Liver Disorders 1: Splanchnic Vein Thrombosis -- Portal Vein Thrombosis: Anticoagulation Vs. Interventional Radiology -- Staging of Portal Vein Thrombosis: Recurrent Thrombosis and Prognostic Factors for Recurrence in Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis (PVT) -- Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis -- Splanchnic Vein Thrombosis: Consensus Statements of Panel 8 -- Part XI Vascular Liver Disorders 2: Other Issues in Vascular Liver Disorders -- Porto-Sinusoidal Vascular Disorder -- Anticoagulation in Splanchnic Vein Thrombosis With and Without Underlying Liver Disease -- Medical Approach to Fontan Patients -- Other Issues in Vascular Liver Disorders: Consensus Statements of Panel 9.
|
| 903 |
|
|
|a SPRING-MED2022
|
| 994 |
|
|
|a 92
|b HCD
|